Company: IMRX
Filing Date: 2025-05-05
Form Type: 10-Q
Source: 0001790340-25-000061
Chunk: 349

Company: Immuneering Corp
Filing Date: 2025-05-05
Form: 10-Q
Item: Part I, Item 1
Chunk 349
---
046)$(14,307)$(739)5.2 %

Research and Development

The following table summarizes the components of our research and development expenses for the periods indicated:

Three Months Ended March 31,Change20252024$%(in thousands, except percentages)Direct research and development expenses by program:IMM-1-104$4,258 $3,646 $612 16.8 %IMM-6-4151,624 1,028 596 58.0 %Other programs1,242 2,051 (809)(39.4)%Indirect research and development expenses:Employee-related costs3,223 3,540 (317)(9.0)%Stock-based compensation expense733 567 166 29.3 %Facilities and other expenses331 309 22 7.1 %Depreciation/amortization61 61 — — %Total research and development$11,472 $11,202 $270 2.4 %

Research and development expenses increased by approximately $0.3 million, or 2.4%, to approximately $11.5 million for the three months ended March 31, 2025 as compared to approximately $11.2 million for the three months ended March 31, 2024. The increase of approximately $0.3 million was primarily due to an increase of approximately $0.4 million related to direct research and development expenses, including a $0.6 million increase in expenses related to IMM-1-104 and a $0.6 million increase in expenses related to IMM-6-415, offset by decreased preclinical spend of approximately $0.8 million due to the Company's prioritization of IMM-1-104. The remaining variance was driven by a decrease in unallocated research and development expenses of approximately $0.1 million, which was primarily driven by decreased employee-related costs (including due to a lower employee headcount) of $0.3 million, offset by increased stock-based compensation costs of $0.2 million, in addition to facilities and other expenses of $22 thousand.

27

General and Administrative

The following table summarizes the components of our general and administrative expenses for the periods indicated:

Three Months Ended March 31,Change20252024$% (in thousands, except percentages)Employee-related costs$2,156 $2,188 $(32)(1.5)%Stock-based compensation expense